Dapagliflozin has been investigated either as monotherapy or as an adjunct treatment with insulin or other oral hypoglycemic agents. Dapagliflozin was originally approved by the FDA on Jan 08, 2014, to improve glycemic control in adults with type 2 diabetes in conjunction with diet and exercise. It was later approved to reduce the risk of kidney function decline, kidney failure, cardiovascular death, and hospitalization for heart failure in adults with chronic kidney disease in April 2021.
*The following content is generated by AI and is for reference only.
Dapagliflozin is a potent and selective inhibitor of sodium-glucose cotransporter 2 (SGLT2), primarily utilized in the management of type 2 diabetes mellitus. Its molecular formula is C21H25NO8, and it is identified by the CAS registry number 872034-63-0. Structurally, Dapagliflozin belongs to the class of gliflozins, characterized by a specific glycosidic linkage that enables high affinity for the SGLT2 protein located in the proximal convoluted tubules of the kidney. By blocking this transporter, the drug effectively prevents the reabsorption of filtered glucose, thereby promoting urinary glucose excretion and lowering blood plasma glucose levels independent of insulin secretion or sensitivity.
Beyond its primary indication for glycemic control, clinical evidence has established Dapagliflozin as a crucial therapeutic agent for reducing the risk of cardiovascular death and hospitalization for heart failure in patients with type 2 diabetes, chronic kidney disease, or established cardiovascular conditions. This dual benefit has revolutionized treatment guidelines, positioning SGLT2 inhibitors as first-line therapies alongside metformin. The medication is typically administered orally once daily, often in tablet form, with dosages adjusted based on individual patient response and renal function. Common side effects include genital mycotic infections due to glucosuria and volume depletion, necessitating careful monitoring of hydration status. Notably, Dapagliflozin does not typically cause hypoglycemia when used as monotherapy, enhancing its safety profile compared to older antidiabetic agents like sulfonylureas. As research continues, ongoing studies are exploring its potential benefits in non-diabetic populations with heart failure and chronic kidney disease, further solidifying its role as a cornerstone in modern metabolic and cardiovascular care. Its mechanism offers a unique physiological approach to managing complex metabolic disorders, addressing both hyperglycemia and associated organ damage.